A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Sarcoma Clinical Trial

Official title:

A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04906876
• Other study ID #: BrUOG 398
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 2021
• Est. completion date: July 2025

Study information

• Verified date: July 2021
• Source: Brown University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.

This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma.

Stratum A: Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Stratum B: Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Disease response assessment will be performed every 2 cycles (6 weeks) for the first 8 cycles (24 weeks), then every 12 weeks thereafter.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2025
• Est. primary completion date: July 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:

• Stratum A: Patients must have histologically confirmed grade 2 or 3 soft tissue sarcoma that is locally advanced and unresectable, or metastatic, consisting of one of the following subtypes: undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma), myxofibrosarcoma, leiomyosarcoma, liposarcoma (excluding well-differentiated), angiosarcoma, synovial sarcoma, rhabdomyosarcoma, spindle cell sarcoma and high-grade sarcoma NOS.

• Stratum B: Patients must have histologically confirmed bone sarcoma that is relapsed or refractory following front-line therapy consisting of one of the following subtypes: osteosarcoma and Ewing sarcoma.

• Patients must have at least one site of measurable disease by RECIST 1.1. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.

• Stratum A: No more than three prior lines of systemic therapy. Of note, anthracycline-based chemotherapy is generally considered first-line therapy. Previously untreated patients may be enrolled at the discretion of the treating investigator.

• Stratum B: At least one prior line of systemic therapy.

• Age =10 years.

• Lansky score =50 for patients <16 years or ECOG performance status =2 for patients =16 years (Karnofsky =50%, see Appendix A).

• Life expectancy of greater than 12 weeks.

• Patients must have adequate organ and marrow function as defined below:

• Hemoglobin =8 g/dl

• absolute neutrophil count =1,000/mcL

• platelets =100,000/mcL (transfusion independent)

• total bilirubin =1.5x institutional upper limit of normal (ULN) (<3.0 mg/dL and direct bilirubin <1.5 mg/dL if documented Gilbert's syndrome)

• AST(SGOT)/ALT(SGPT) =3x institutional ULN (= 5 x ULN if liver metastases present)

• creatinine =1.5x institutional ULN OR

• glomerular filtration rate (GFR) =50 mL/min/1.73 m2

• PT/INR =1.5x institutional ULN

• Amylase and lipase =1.5x institutional ULN

• Washout period prior to Cycle 1, Day 1:

• = 21 days since last dose of chemotherapy, immunotherapy, or therapeutic radiation treatment.

• = 28 days since last tyrosine kinase inhibitor (or 5 half-lives, whichever is shorter).

• = 7 days since last focal palliative radiation treatment.

• = 28 days since major surgical procedure.

• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.

• Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

• Women of child-bearing potential must have a negative serum or urine pregnancy test at registration and within 7 days of first study therapy.

• The effects of 9-ING-41 on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women may not be breastfeeding during study participation. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of 9-ING-41 administration.

• Patients must agree to provide tumor tissue, either fresh or archival specimen of primary tumor and/or metastatic lesion. If tumor tissue is not available, then discuss with principal investigator.

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients with sarcoma histologies other than those listed above will be excluded.

• Prior treatment with 9-ING-41, gemcitabine, or docetaxel.

• Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.

• Patients who are receiving any other investigational agents for treatment of their sarcoma.

• Patients who are pregnant or lactating.

• Patients with untreated brain or meningeal metastases. Subjects with history of metastases are eligible provided they do not require ongoing steroid treatment and have shown clinical and radiographic stability for at least 14 days after definitive therapy.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to 9-ING-41, gemcitabine, docetaxel, or other agents used in study.

• Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Has had a previous (within 2 years) or has a current malignancy other than the target cancer with the exception of curatively treated local tumors including carcinoma in situ of the breast or cervix, basal or squamous cell carcinoma of the skin, or prostate cancer with Gleason Grade < 6 and prostate-specific antigen within normal range.

• Has any medical and/or social condition that, in the opinion of the investigator would preclude study participation.

Related Conditions & MeSH terms

• Angiosarcoma
• Bone Sarcoma
• High Grade Sarcoma
• Histiocytoma, Malignant Fibrous
• Leiomyosarcoma
• Liposarcoma
• Metastatic Sarcoma
• Myxofibrosarcoma
• Rhabdomyosarcoma
• Sarcoma
• Sarcoma, Synovial
• Soft Tissue Sarcoma
• Spindle Cell Sarcoma
• Synovial Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Intervention

Drug:
• Gemcitabine
Gemcitabine as a 90-minute IV infusion
• Docetaxel
Docetaxel as a 60-minute IV infusion
• 9-ING-41
9-ING-41 as an IV infusion over 1-4 hours twice weekly

Locations

Country	Name	City	State
United States	Hasbro Children's Hospital	Providence	Rhode Island
United States	Lifespan Cancer Insitute	Providence	Rhode Island

Sponsors (2)

Lead Sponsor	Collaborator
Brown University	Actuate Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Control Rate	To determine the Disease Control Rate (DCR = Complete Response [CR] + Partial Response [PR] + Stable Disease [SD] at 6 months) of 9-ING-41 in combination with gemcitabine and docetaxel in advanced sarcoma.	Approximately 24 weeks
Secondary	Progression Free Survival	To determine the activity of 9-ING-41 with chemotherapy by assessing progression free survival (PFS).	From start of protocol therapy, approximately 5 years